Sutro Biopharma (STRO) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Sutro Biopharma is scheduled to release its Q2 2025 quarterly earnings on Tuesday, August 12th, with analysts predicting a loss of ($0.53) per share and revenue of $14.55 million.
• The company reported a loss of ($0.91) per share in its previous earnings announcement, which was below analysts' expectations of ($0.63), despite revenue exceeding estimates.
• Institutional investors own 96.99% of Sutro Biopharma, with notable increases in stakes by firms like AQR Capital Management, which raised its stake by 1,052.8%.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) is expected to post its Q2 2025 quarterly earnings results before the market opens on Tuesday, August 12th. Analysts expect Sutro Biopharma to post earnings of ($0.53) per share and revenue of $14.55 million for the quarter.

Sutro Biopharma (NASDAQ:STRO - Get Free Report) last posted its earnings results on Tuesday, August 12th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.39. Sutro Biopharma had a negative net margin of 201.32% and a negative return on equity of 481.57%. The business had revenue of $63.74 million for the quarter, compared to analyst estimates of $14.55 million. On average, analysts expect Sutro Biopharma to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Sutro Biopharma Price Performance

Sutro Biopharma stock traded up $0.00 during midday trading on Friday, hitting $0.80. 311,211 shares of the stock were exchanged, compared to its average volume of 462,126. Sutro Biopharma has a 1 year low of $0.52 and a 1 year high of $5.17. The firm has a market cap of $67.77 million, a P/E ratio of -0.32 and a beta of 1.66. The company has a 50 day moving average price of $0.81 and a two-hundred day moving average price of $1.03.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Invesco Ltd. grew its position in Sutro Biopharma by 137.8% in the 1st quarter. Invesco Ltd. now owns 92,139 shares of the company's stock worth $60,000 after purchasing an additional 53,390 shares during the last quarter. Strs Ohio bought a new position in Sutro Biopharma in the 1st quarter worth about $99,000. Finally, AQR Capital Management LLC grew its position in Sutro Biopharma by 1,052.8% in the 1st quarter. AQR Capital Management LLC now owns 1,320,917 shares of the company's stock worth $859,000 after purchasing an additional 1,206,330 shares during the last quarter. Institutional investors own 96.99% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on STRO. HC Wainwright reiterated a "neutral" rating and issued a $2.00 price objective on shares of Sutro Biopharma in a report on Tuesday, April 29th. Bank of America cut their price objective on shares of Sutro Biopharma from $1.00 to $0.80 and set an "underperform" rating on the stock in a report on Monday, May 19th. Piper Sandler upgraded shares of Sutro Biopharma from a "neutral" rating to an "overweight" rating and set a $2.00 price objective on the stock in a report on Monday, June 16th. Finally, Wall Street Zen upgraded shares of Sutro Biopharma from a "sell" rating to a "hold" rating in a report on Saturday. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $6.11.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.